Latest news

• Study shows Otsuka's TB drug works even in worst cases

  Typically, it occurs in patients who do not take their drugs as indicated by their doctor, and was first identified as a sub-category of MDR-TB in 2006. ... Around 9% of the 480, 000 MDR-TB cases estimated to have occurred in 2013 are thought to actually

• R&D productivity takes off

  nitro-dihydro-imidazooxazole drug for multidrug-resistant tuberculosis (MDR-TB); Gilead Sciences' Zydelig (idelalisib) for certain types of leukaemia and lymphoma, which inhibits a protein that plays a role in the

• Novartis' Bexsero triumphs at UK Prix Galien

  The novel treatment for pulmonary multi‐drug resistant tuberculosis (MDR‐TB) is administered by directly observed therapy and indicated as part of combination therapy in adults with pulmonary MDR‐TB. ... MDR‐TB and preventing progression to more

• Otsuka wins approval for TB drug Deltyba

  According to the World Health Organization (WHO), there are about 170, 000 deaths globally each year due to MDR-TB. ... Both trials arms also received other therapies. Akihiko Otsuka, chairman of Otsuka, said that MDR-TB remained a “serious problem”

• Tuberculosis: treatment and prevention

  Multi drug-resistant TB (MDR-TB) is defined as resistance to the gold standard treatment of isoniazid and rifampicin. ... Bedaquiline has been approved for use as part of combination therapy, in adult patients with MDR-TB and has been shown to be active